The stable outlook reflects our expectation that Nan Shan Life's capital adequacy will remain sound over the coming two years, given the insurer's moderate premium growth path. That is despite a likely shift in Nan Shan Life's investment allocation toward equity-like investments. We also believe the insurer will maintain close monitoring of its investment risk exposure to prevent further deterioration from the current moderate risk level. In addition, the stable outlook reflects our view that Nan Shan Life's operations will remain independent from its two main shareholders, Taiwan-based Ruentex and Pou Chen Corp. groups, under Taiwan's regulatory framework for financial service sectors. We may raise the ratings if Nan Shan Life demonstrates sustainable restoration of its franchise and business value